CalciMedica Announces Publication in JCI Insight of Preclinical Data Supporting CRAC Channel Inhibitor as a Potential Therapy for Pulmonary Arterial Hypertension

CRAC Channel Inhibitor for PAH: Preclinical data suggests that CM5480, a CRAC channel inhibitor, may serve as a first-in-class therapy for pulmonary arterial hypertension (PAH), showing efficacy both as a standalone treatment and in combination with existing therapies.

Mechanism and Benefits: The study demonstrated that CM5480 significantly reduced pulmonary neomuscularization, right ventricular systolic pressure, and right ventricular hypertrophy in animal models, indicating its potential to improve cardiac function and pulmonary vascular remodeling.

Combination Therapy Efficacy: Combining CM5480 with standard PAH treatments like ambrisentan or sildenafil yielded greater therapeutic benefits than using these therapies alone, highlighting the importance of targeting multiple pathways in PAH treatment.

Implications for Acute Kidney Injury: The findings also suggest that CRAC channel inhibition could improve right ventricular dysfunction in patients with sepsis, which is a leading cause of acute kidney injury, with ongoing trials expected to provide further insights by 2026.